121 related articles for article (PubMed ID: 2133429)
1. Thromboxane synthesis inhibition increases renal prostacyclin and prevents renal disease progression in rats with remnant kidney.
Zoja C; Perico N; Corna D; Benigni A; Gabanelli M; Morigi M; Bertani T; Remuzzi G
J Am Soc Nephrol; 1990 Nov; 1(5):799-807. PubMed ID: 2133429
[TBL] [Abstract][Full Text] [Related]
2. Effects of OKY-046, a selective thromboxane synthetase inhibitor, on blood pressure and thromboxane synthesis in spontaneously hypertensive rats.
Gomi T; Ikeda T; Ishimitsu T; Uehara Y
Prostaglandins Leukot Essent Fatty Acids; 1989 Sep; 37(3):139-44. PubMed ID: 2608692
[TBL] [Abstract][Full Text] [Related]
3. Selective inhibition of platelet thromboxane generation with low-dose aspirin does not protect rats with reduced renal mass from the development of progressive disease.
Zoja C; Benigni A; Livio M; Bergamelli A; Orisio S; Abbate M; Bertani T; Remuzzi G
Am J Pathol; 1989 May; 134(5):1027-38. PubMed ID: 2497648
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of thromboxane synthesis ameliorates the progressive kidney disease of rats with subtotal renal ablation.
Purkerson ML; Joist JH; Yates J; Valdes A; Morrison A; Klahr S
Proc Natl Acad Sci U S A; 1985 Jan; 82(1):193-7. PubMed ID: 3855542
[TBL] [Abstract][Full Text] [Related]
5. Effect of the infusion of OKY-046, a thromboxane A2 synthase inhibitor, on urinary metabolites of prostacyclin and thromboxane A2 in healthy human subjects.
Morio H; Hirai A; Terano T; Tamura Y; Yoshida S
Thromb Haemost; 1993 Mar; 69(3):276-81. PubMed ID: 8470052
[TBL] [Abstract][Full Text] [Related]
6. The effect of a thromboxane synthetase inhibitor, OKY-046, on urinary excretion of immunoreactive thromboxane B2 and 6-keto-prostaglandin F1 alpha in patients with ischemic cerebrovascular disease.
Uyama O; Nagatsuka K; Nakabayashi S; Isaka Y; Yoneda S; Kimura K; Abe H
Stroke; 1985; 16(2):241-4. PubMed ID: 3883580
[TBL] [Abstract][Full Text] [Related]
7. Intravenous infusion of a selective inhibitor of thromboxane A2 synthetase in man: influence on thromboxane B2 and 6-keto-prostaglandin F1 alpha levels and platelet aggregation.
Yui Y; Hattori R; Takatsu Y; Nakajima H; Wakabayashi A; Kawai C; Kayama N; Hiraku S; Inagawa T; Tsubojima M
Circulation; 1984 Oct; 70(4):599-605. PubMed ID: 6434196
[TBL] [Abstract][Full Text] [Related]
8. Effect of selective inhibition of thromboxane synthesis on renal function in diabetic nephropathy.
Kontessis PS; Jones SL; Barrow SE; Stratton PD; Alessandrini P; De Cosmo S; Ritter JM; Viberti GC
J Lab Clin Med; 1993 Mar; 121(3):415-23. PubMed ID: 8445289
[TBL] [Abstract][Full Text] [Related]
9. Effects of selective inhibition of thromboxane synthesis on renal function in humans.
Zipser RD
Am J Physiol; 1985 Jun; 248(6 Pt 2):F753-6. PubMed ID: 3839111
[TBL] [Abstract][Full Text] [Related]
10. Effects of a selective thromboxane synthetase inhibitor OKY-046 on experimental diabetic nephropathy.
Hora K; Oguchi H; Furukawa T; Hora K; Tokunaga S
Nephron; 1990; 56(3):297-305. PubMed ID: 2077412
[TBL] [Abstract][Full Text] [Related]
11. Urinary excretion of thromboxane and prostacyclin metabolites during chronic low-dose aspirin: evidence for an extrarenal origin of urinary thromboxane B2 and 6-keto-prostaglandin F1 alpha in healthy subjects.
Chiabrando C; Rivoltella L; Martelli L; Valzacchi S; Fanelli R
Biochim Biophys Acta; 1992 Feb; 1133(3):247-54. PubMed ID: 1737057
[TBL] [Abstract][Full Text] [Related]
12. Increased thromboxane biosynthesis in a human preparation of platelet activation: biochemical and functional consequences of selective inhibition of thromboxane synthase.
Reilly IA; Doran JB; Smith B; FitzGerald GA
Circulation; 1986 Jun; 73(6):1300-9. PubMed ID: 2938849
[TBL] [Abstract][Full Text] [Related]
13. The role of thromboxane in two-kidney, one-clip Goldblatt hypertension in rats.
Himmelstein SI; Klotman PE
Am J Physiol; 1989 Aug; 257(2 Pt 2):F190-6. PubMed ID: 2527469
[TBL] [Abstract][Full Text] [Related]
14. Selective inhibition of renal thromboxane biosynthesis increased sodium excretion rate in normal and saline-loaded rats.
Papanicolaou N; Gkika EL; Gkikas G; Bariety J
Clin Sci (Lond); 1985 Jan; 68(1):79-82. PubMed ID: 3880524
[TBL] [Abstract][Full Text] [Related]
15. Thromboxane synthase inhibition: "endoperoxide shunt phenomenon" does not occur in healthy humans in vivo.
Henriksson P; Rasmanis G; Edhag O; Vesterqvist O; Gréen K
Prostaglandins; 1990 Jan; 39(1):99-107. PubMed ID: 2106716
[TBL] [Abstract][Full Text] [Related]
16. Ticlopidine prevents renal disease progression in rats with reduced renal mass.
Zoja C; Perico N; Bergamelli A; Pasini M; Morigi M; Dadan J; Belloni A; Bertani T; Remuzzi G
Kidney Int; 1990 Mar; 37(3):934-42. PubMed ID: 2313981
[TBL] [Abstract][Full Text] [Related]
17. Thromboxane synthesis and blood pressure in spontaneously hypertensive rats.
Purkerson ML; Martin KJ; Yates J; Kissane JM; Klahr S
Hypertension; 1986 Dec; 8(12):1113-20. PubMed ID: 3793195
[TBL] [Abstract][Full Text] [Related]
18. Effect of DP-1904, a thromboxane A2 synthetase inhibitor, on crescentic nephritis in rats.
Nagao T; Ito M; Nagamatsu T; Suzuki Y
Eur J Pharmacol; 1994 Jul; 259(3):233-42. PubMed ID: 7982449
[TBL] [Abstract][Full Text] [Related]
19. A comparative evaluation of thromboxane receptor blockade, thromboxane synthase inhibition and both in animal models of arterial thrombosis.
Salvati P; Dho L; Ukmar G; Vaga L; Rimoldi O; Patrono C
J Pharmacol Exp Ther; 1994 Apr; 269(1):238-45. PubMed ID: 8169831
[TBL] [Abstract][Full Text] [Related]
20. Influence of selective thromboxane synthetase blocker CGS-13080 on thromboxane and prostacyclin biosynthesis in whole blood: evidence for synthesis of prostacyclin by leukocytes from platelet-derived endoperoxides.
Mehta J; Mehta P; Lawson DL; Ostrowski N; Brigmon L
J Lab Clin Med; 1985 Sep; 106(3):246-52. PubMed ID: 3928780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
